PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30898550-0	2019	Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial.	Deferoxamine	0-21	UTP25 small subunit processome component	Homo sapiens	68-71	
23943316-11	2013	CONCLUSIONS: The Hi-Def trial is expected to advance our understanding of the pathopgysiology of secondary neuronal injury in ICH and will provide a crucial "Go/No Go" signal as to whether a Phase III trial to investigate the efficacy of DFO is warranted.	Deferoxamine	238-241	UTP25 small subunit processome component	Homo sapiens	20-23